Cresset Asset Management, LLC Anavex Life Sciences Corp. Transaction History

Cresset Asset Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$5.04 - $9.95 $50 - $99	-10 Reduced 0.1%	10,440 $97,000
Q3 2023 Nov 14, 2023	SELL	$6.55 - $9.37 $1,637 - $2,342	-250 Reduced 2.34%	10,450 $68,000
Q4 2022 Feb 14, 2023	BUY	$7.65 - $14.43 $1,912 - $3,607	250 Added 2.39%	10,700 $99,000
Q4 2021 Feb 10, 2022	SELL	$16.88 - $23.31 $1,755 - $2,424	-104 Reduced 0.99%	10,450 $181,000
Q3 2021 Nov 15, 2021	BUY	$16.82 - $25.75 $177,518 - $271,765	10,554 New	10,554 $190,000

154

27.3M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $581M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Cresset Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Cresset Asset Management, LLC with notifications on news.